Drug May Reverse Resistance to Targeted Therapy in Lung Cancer

Share this content:

the Cancer Therapy Advisor take:

Resistance to targeted therapy is not uncommon in patients with lung cancer, but a new study published in the Journal of Clinical Investigation may be a game changer in this field.


According to the study, researchers have identified the mechanisms through which resistance occurs and have discovered a drug that may combat it.


In their study, researchers employed animal models and evaluation in cell lines. They found that erlotinib resistance in lung cancer cells may be due to over-expression of a growth protein called Cripto-1. Blocking signaling transduction of this protein, however, brought back sensitivity to the drug.


To accomplish blocking of Cripto-1 signaling transduction, the researchers used a Src inhibitor that is unfortunately no longer available, but the FDA has approved a similar Src inhibitor for chronic myelogenous leukemia.


The researchers are already looking at ways to further investigate Cripto-1 as a potential target in treating lung cancer. For instance, they are initiating a clinical trial to determine whether their observations in this study hold true in patients with non-small cell lung cancer as well as in animals and in the lab. In particular, they plan to include patients with EGFR mutations, as they are most sensitive to erlotinib, the researchers said.

Drug May Reverse Resistance to Targeted Therapy in Lung Cancer
Drug May Reverse Resistance to Targeted Therapy in Lung Cancer
Scientists at Georgetown Lombardi Comprehensive Cancer Center and the National Cancer Institute have discovered why intrinsic resistance occurs to lung cancer targeted therapy—and they have pinpointed a type of drug they say could potentially reverse it.
READ FULL ARTICLE From National Cancer Institute

Related Resources

Related Slideshows

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs